UK Pompe Disease Launch Readiness

Alglucosidase alfa (Lumizyme/Myozyme, Sanofi) is NHS England's commissioned late-onset Pompe (LOPD) standard, delivered via NHS clinical and commissioning policy rather than a formal NICE Technology Appraisal, reaching roughly 280-350 of the UK's 350-450 total Pompe patients (200-250 specifically LOPD) at the 8 NHS Pompe Highly Specialised Service centres, anchored by Royal Free London's ~80-100 patient cohort. Avalglucosidase alfa (Nexviazyme, Sanofi), the next-generation ERT, already has a published, positive NICE recommendation (TA821, 24 August 2022) that defines the switch criteria from alglucosidase for every subsequent submission. But the economics behind that recommendation show how hard the comparator is to clear: avalglucosidase's incremental clinical benefit over alglucosidase (COMET: +23.5m 6MWT) translates to a small QALY increment against a materially higher list price, and NICE's positive decision rested on a substantial confidential patient access scheme that narrowed the ICER inside HST bounds — a negotiating position built on Sanofi's existing alglucosidase franchise that a new entrant without that installed base could not easily replicate.

A materially more favourable NICE case exists in the anti-drug-antibody-positive (ADA+) inadequate-responder subgroup: an estimated 30-50 UK LOPD patients on alglucosidase develop high-titre ADA and experience measurable clinical deterioration (documented FVC decline and cardiac LVH progression) despite continued ERT. A drug positioned specifically for this cohort is assessed against a baseline of ongoing deterioration rather than incremental improvement, and the QALY model shifts accordingly: avoiding ventilator dependency carries a large utility gain (EQ-5D mechanical-ventilation utility ~0.32 vs ~0.68 non-ventilated, roughly 0.36 QALY/year for each year of ventilation avoided). The 80-120 UK LOPD patients on home non-invasive ventilation (NIV), with FVC below 50% predicted and faster decline on inadequate ERT, represent the highest-urgency and strongest evidence-base subgroup for this positioning.

The pre-launch imperative is to build a standalone ADA+ NICE submission rather than compete in the avalglucosidase incremental-improvement comparison. NICE's HST pathway (patients under the 350-450 UK total, QALY threshold £100,000-300,000) is more accessible than standard TA and the natural route for this positioning. Formal engagement with the British Inherited Metabolic Diseases Group's Pompe subcommittee (6 metabolic physicians across the 8 NHS HSS centres who directly advise NICE) should begin 18-24 months pre-submission (typical budget £50,000-100,000 over 2-3 years), alongside a Royal Free London data-access partnership for ADA-titre and NIV-dependency cohort characterisation, since ADA testing and identification is a commercial prerequisite: without an identified ADA+ population, there is no NICE-eligible cohort to submit against.

This assessment synthesises three research angles into a single UK Pompe disease launch readiness view: competitive positioning against alglucosidase and avalglucosidase, ADA+/NIV-dependent population sizing anchored in Royal Free London and NHS Pompe HSS data, and anticipated NICE/NHS payer posture derived from the TA821 HST precedent and NHS's alglucosidase commissioning policy.

Sources: NHS England alglucosidase clinical/commissioning policy documentation; NICE TA821 avalglucosidase decision document (24 August 2022); COMET incremental-benefit and ICER analysis; BIMDG Pompe subcommittee guidance; Royal Free London metabolic service published outcomes; NHS England Pompe Highly Specialised Service specification.